| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| UNITED STATES | Region | 2025 | USD | 33,279.0 | 96.8% |
| Other Region | Region | 2025 | USD | 1,087.0 | 3.2% |
| UNITED STATES | Region | 2024 | USD | 34,105.0 | 70.6% |
| Rest Of World | Region | 2024 | USD | 13,199.0 | 27.3% |
| Other Region | Region | 2024 | USD | 996.0 | 2.1% |
| UNITED STATES | Region | 2023 | USD | 31,555.0 | 70.1% |
| Rest Of World | Region | 2023 | USD | 12,752.0 | 28.3% |
| Other Region | Region | 2023 | USD | 699.0 | 1.6% |
| UNITED STATES | Region | 2022 | USD | 31,828.0 | 69.0% |
| Europe | Region | 2022 | USD | 13,497.0 | 29.2% |
| Other Region | Region | 2022 | USD | 834.0 | 1.8% |
| UNITED STATES | Region | 2021 | USD | 29,214.0 | 63.0% |
| Europe | Region | 2021 | USD | 10,687.0 | 23.0% |
| Rest Of World | Region | 2021 | USD | 5,632.0 | 12.1% |
| Other Region | Region | 2021 | USD | 852.0 | 1.8% |
| UNITED STATES | Region | 2020 | USD | 26,577.0 | 62.5% |
| Europe | Region | 2020 | USD | 9,853.0 | 23.2% |
| Rest Of World | Region | 2020 | USD | 5,457.0 | 12.8% |
| Other Region | Region | 2020 | USD | 631.0 | 1.5% |
| Eliquis | Product | 2025 | USD | 14,443.0 | 30.0% |
| Opdivo | Product | 2025 | USD | 10,049.0 | 20.9% |
| Orencia | Product | 2025 | USD | 3,705.0 | 7.7% |
| Revlimid | Product | 2025 | USD | 2,951.0 | 6.1% |
| Yervoy | Product | 2025 | USD | 2,900.0 | 6.0% |
| Pomalyst/Imnovid | Product | 2025 | USD | 2,733.0 | 5.7% |
| Reblozyl | Product | 2025 | USD | 2,327.0 | 4.8% |
| Other Growth Brands | Product | 2025 | USD | 1,924.0 | 4.0% |
| Breyanzi | Product | 2025 | USD | 1,358.0 | 2.8% |
| Opdualag | Product | 2025 | USD | 1,185.0 | 2.5% |
| Camzyos | Product | 2025 | USD | 1,068.0 | 2.2% |
| Other Legacy Brands | Product | 2025 | USD | 798.0 | 1.7% |
| Zeposia | Product | 2025 | USD | 577.0 | 1.2% |
| Sprycel | Product | 2025 | USD | 493.0 | 1.0% |
| Abecma | Product | 2025 | USD | 427.0 | 0.9% |
| Abraxane | Product | 2025 | USD | 368.0 | 0.8% |
| Sotyktu | Product | 2025 | USD | 291.0 | 0.6% |
| Opdivo Ovantig | Product | 2025 | USD | 238.0 | 0.5% |
| Krazati | Product | 2025 | USD | 205.0 | 0.4% |
| Cobenfy | Product | 2025 | USD | 155.0 | 0.3% |
| Eliquis | Product | 2024 | USD | 13,333.0 | 27.6% |
| Opdivo | Product | 2024 | USD | 9,304.0 | 19.3% |
| Revlimid | Product | 2024 | USD | 5,773.0 | 12.0% |
| Orencia | Product | 2024 | USD | 3,682.0 | 7.6% |
| Pomalyst/Imnovid | Product | 2024 | USD | 3,545.0 | 7.4% |
| Yervoy | Product | 2024 | USD | 2,530.0 | 5.2% |
| Reblozyl | Product | 2024 | USD | 1,773.0 | 3.7% |
| Other Growth Brands | Product | 2024 | USD | 1,605.0 | 3.3% |
| Sprycel | Product | 2024 | USD | 1,286.0 | 2.7% |
| Opdualag | Product | 2024 | USD | 928.0 | 1.9% |
| Other Legacy Brands | Product | 2024 | USD | 925.0 | 1.9% |
| Abraxane | Product | 2024 | USD | 875.0 | 1.8% |
| Breyanzi | Product | 2024 | USD | 747.0 | 1.6% |
| Camzyos | Product | 2024 | USD | 602.0 | 1.3% |
| Zeposia | Product | 2024 | USD | 566.0 | 1.2% |
| Abecma | Product | 2024 | USD | 406.0 | 0.8% |
| Sotyktu | Product | 2024 | USD | 246.0 | 0.5% |
| Krazati | Product | 2024 | USD | 126.0 | 0.3% |
| Cobenfy | Product | 2024 | USD | 10.0 | 0.0% |
| Eliquis | Product | 2023 | USD | 12,206.0 | 28.5% |
| Opdivo | Product | 2023 | USD | 9,009.0 | 21.0% |
| Revlimid | Product | 2023 | USD | 6,097.0 | 14.2% |
| Orencia | Product | 2023 | USD | 3,601.0 | 8.4% |
| Pomalyst/Imnovid | Product | 2023 | USD | 3,441.0 | 8.0% |
| Yervoy | Product | 2023 | USD | 2,238.0 | 5.2% |
| Sprycel | Product | 2023 | USD | 1,930.0 | 4.5% |
| Reblozyl | Product | 2023 | USD | 1,008.0 | 2.4% |
| Abraxane | Product | 2023 | USD | 1,004.0 | 2.3% |
| Opdualag | Product | 2023 | USD | 627.0 | 1.5% |
| Abecma | Product | 2023 | USD | 472.0 | 1.1% |
| Zeposia | Product | 2023 | USD | 434.0 | 1.0% |
| Breyanzi | Product | 2023 | USD | 364.0 | 0.9% |
| Camzyos | Product | 2023 | USD | 231.0 | 0.5% |
| Sotyktu | Product | 2023 | USD | 170.0 | 0.4% |
| Eliquis | Product | 2022 | USD | 11,789.0 | 25.8% |
| Revlimid | Product | 2022 | USD | 9,978.0 | 21.9% |
| Opdivo | Product | 2022 | USD | 8,249.0 | 18.1% |
| Pomalyst/Imnovid | Product | 2022 | USD | 3,497.0 | 7.7% |
| Orencia | Product | 2022 | USD | 3,464.0 | 7.6% |
| Sprycel | Product | 2022 | USD | 2,165.0 | 4.7% |
| Yervoy | Product | 2022 | USD | 2,131.0 | 4.7% |
| Mature Products And All Other | Product | 2022 | USD | 1,749.0 | 3.8% |
| Abraxane | Product | 2022 | USD | 811.0 | 1.8% |
| Reblozyl | Product | 2022 | USD | 717.0 | 1.6% |
| Abecma | Product | 2022 | USD | 388.0 | 0.9% |
| Opdualag | Product | 2022 | USD | 252.0 | 0.6% |
| Zeposia | Product | 2022 | USD | 250.0 | 0.6% |
| Breyanzi | Product | 2022 | USD | 182.0 | 0.4% |
| Camzyos | Product | 2022 | USD | 24.0 | 0.1% |
| Sotyktu | Product | 2022 | USD | 8.0 | 0.0% |
| Revlimid | Product | 2021 | USD | 12,821.0 | 27.9% |
| Eliquis | Product | 2021 | USD | 10,762.0 | 23.4% |
| Opdivo | Product | 2021 | USD | 7,523.0 | 16.4% |
| Pomalyst/Imnovid | Product | 2021 | USD | 3,332.0 | 7.3% |
| Orencia | Product | 2021 | USD | 3,306.0 | 7.2% |
| Sprycel | Product | 2021 | USD | 2,117.0 | 4.6% |
| Yervoy | Product | 2021 | USD | 2,026.0 | 4.4% |
| Mature Products And All Other | Product | 2021 | USD | 1,900.0 | 4.1% |
| Abraxane | Product | 2021 | USD | 1,181.0 | 2.6% |
| Reblozyl | Product | 2021 | USD | 551.0 | 1.2% |
| Abecma | Product | 2021 | USD | 164.0 | 0.4% |
| Zeposia | Product | 2021 | USD | 134.0 | 0.3% |
| Breyanzi | Product | 2021 | USD | 87.0 | 0.2% |
| Revlimid | Product | 2020 | USD | 12,106.0 | 28.8% |
| Eliquis | Product | 2020 | USD | 9,168.0 | 21.8% |
| Opdivo | Product | 2020 | USD | 6,992.0 | 16.7% |
| Orencia | Product | 2020 | USD | 3,157.0 | 7.5% |
| Pomalyst/Imnovid | Product | 2020 | USD | 3,070.0 | 7.3% |
| Sprycel | Product | 2020 | USD | 2,140.0 | 5.1% |
| Yervoy | Product | 2020 | USD | 1,682.0 | 4.0% |
| Mature Products And All Other | Product | 2020 | USD | 1,315.0 | 3.1% |
| Abraxane | Product | 2020 | USD | 1,247.0 | 3.0% |
| Baraclude | Product | 2020 | USD | 447.0 | 1.1% |
| Empliciti | Product | 2020 | USD | 381.0 | 0.9% |
| Reblozyl | Product | 2020 | USD | 274.0 | 0.7% |
| Zeposia | Product | 2020 | USD | 12.0 | 0.0% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
